Table 3.
Surgery details
| Cisplatin and fluorouracil (n=451) | Epirubicin, cisplatin, and capecitabine (n=446) | |
|---|---|---|
| Surgery done | ||
| Yes | 411 (91%) | 387 (87%) |
| No | 40 (9%) | 59 (13%) |
| Reason for no surgery* | ||
| CT evidence of disease progression | 13 (33%) | 11 (19%) |
| Clinical evidence of disease progression | 3 (8%) | 6 (10%) |
| Laparoscopic evidence of disease progression | 4 (10%) | 4 (7%) |
| Comorbidity | 6 (15%) | 9 (15%) |
| Patient choice | 2 (5%) | 7 (12%) |
| Patient died | 1 (3%) | 8 (14%) |
| Patient otherwise deemed inoperable | 11 (28%) | 14 (24%) |
| Resection done | ||
| Yes | 387 (86%) | 364 (82%) |
| No (open-close operation) | 24 (5%) | 23 (5%) |
| Surgical approach† | ||
| Abdomen and right chest open | 192 (50%) | 187 (51%) |
| Abdomen (laparoscopic) and right chest open | 108 (28%) | 101 (28%) |
| Left thoracoabdominal incision | 28 (7%) | 24 (7%) |
| Totally laparoscopic | 9 (2%) | 9 (2%) |
| Other | 43 (11%) | 35 (10%) |
| Missing | 7 (2%) | 8 (2%) |
| Location† | ||
| Mid-oesophagus | 72 (19%) | 56 (15%) |
| Siewert type 1 | 227 (59%) | 208 (57%) |
| Siewert type 2 | 76 (20%) | 89 (24%) |
| Missing | 12 (3%) | 11 (3%) |
Data are n (%). An open-close operation was deemed as one in which no resection was done, or the reason given on the case report form for not having surgery was that the patient was found to be inoperable at laparotomy or thoracotomy.
*
Percentages are out of patients who did not have surgery.
†
Percentages are out of all patients who did have resection.